Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cash and texts keep psychosis patients in care?

NCT ID NCT05967195

Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether offering small financial rewards (up to $50/month) and text reminders can encourage people with first-episode psychosis to attend their therapy and medication appointments. About 145 participants from two specialty clinics will take part over three 3-month periods, with adjustments made based on feedback. The goal is to see if this simple approach is acceptable and feasible for patients and clinicians.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
financial incentives and text messages
What this could lead to
If successful, this approach could improve treatment attendance and outcomes for people with early psychosis, reducing risks like suicide.
What could go wrong
This is a very early pilot study with only 145 participants, so results may not apply broadly. The intervention is modest and may not significantly change behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 145 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. For all participants, age ≥ 18 years old. 2. For intervention trial and patient feasibility and acceptability measurement: Patients with first-episode psychosis, enrolled in Coordinated Specialty Care at the Psychosis Education, Assessment, Care and Empowerment (PEACE) clinic and Psychosis Evaluation and Recovery Center (PERC). 3. For clinician feasibility and acceptability measurement at intervention sites: Clinicians working at PEACE and PERC where the intervention will be piloted. 4. For clinician implementation facilitator and barrier assessment at other Connection LHS sites to assess for scalability: Clinicians in Connection LHS who work at sites other than PEACE and PERC.Participants must sign the informed consent form Exclusion Criteria: 1. For intervention trial and patient feasibility and acceptability measurement: Expectation of leaving coordinated specialty care programing within 6 months (which will exclude all of the PI's patient panel) and/or intellectual disability of sufficient degree that the patient's primary psychiatrist expects to compromise capacity to consent to this research and/or psychosis secondary to another medical condition (which may not share the same motivational features that are otherwise understood about the primary psychiatric conditions with psychosis). 2. For clinician feasibility and acceptability measurement at intervention sites: Study investigators who work at these clinics will be excluded from participation in the feasibility and acceptability study component given their role in the trial planning and execution. 3. For clinician implementation facilitator and barrier assessment at other Connection LHS sites to assess for scalability: none.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for First episode psychosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

First episode psychosis

Contacts and locations

Locations

  • PEACE Program, Horizon House, Inc.

    Philadelphia, Pennsylvania, 19123, United States

  • University of North Carolina at Chapel Hill (ENCOMPASS Program)

    Raleigh, North Carolina, 27608, United States

  • University of Pennsylvania

    Philadephia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.